Author: Mahrukh Rehan

GCP Applied Technologies Inc. (GCP) saw a push of 13.06% in premarket. However, the last trading session concluded at $27.02 with a decrease of 1.35%.

North America Concrete Admixtures Price – What’s new?

On 22^nd November 2021, GCP announced that price hikes for Concrete Admixtures will be implemented across North America. Prices for all concrete admixture and fiber products will increase by up to 10% from January 1, 2022, in order to continue offering the great solutions GCP’s clients expect at the levels of service they want.

Now what?

Over the last six months, global supply chain impacts on raw material and freight costs have been unprecedented. The company has been increasing inventory levels to meet the customers’ demands. And they have increased transportation capacity to assure prompt delivery. GCP’s priority is the success of clients and their end-users, as well as the promotion of high-quality, environmentally friendly, and cost-effective building processes. Lastly, GCP’s regional sales team will get in touch with each of the clients to explain the unique consequences for their company.

Third Quarter 2021 Results – Latest Updates by GCP

GCP reported third-quarter 2021 results on 3^rd November 2021. The company reported net sales of $249.6 with an incline of 0.5%. Moreover, higher raw material and shipping expenses resulted in a gross margin of 33.9 percent.

Reduced employee-related expenses as a consequence of restructuring initiatives and lower incentive compensation costs drove down selling, general, and administrative costs to $59.2 million. Furthermore, higher acquisition-related expenditures and building costs associated with the closure of the Cambridge, MA corporate headquarters largely offset these positive effects. Lastly, gross margin fell to 31.0 percent, leading to increasing raw material costs.

So what?

Despite effects in specific areas owing to intermittent pandemic restrictions and supply chain interruptions, demand was in line with anticipated across both the business divisions in the third quarter of 2021. GCP increased average selling price, reduced selling, general, and administrative costs, and increased productivity in our operations throughout the quarter. Furthermore, the cost inflation, particularly raw material prices and transportation, as well as supply chain interruptions, had a significant impact. The conjunction of these variables had a minor effect on revenues, but a major influence on margins. Last but not least, the Specialty Construction Chemicals division had the most effect.

California Resources Corporation (CRC) saw a decrease of 8.75% in aftermarket. However, the last trading session concluded at $40.55 with a decline of 1.51%.

Additional Investor Conference Participation – Updates

On 19^th November 2021, CRC announced that certain company executives will take part in conferences. The Pickering Energy Partners’ Technology, Energy & Mobility Festival will be held on 14-15^th December 2021 while Goldman Sachs’ Global Energy and Clean Technology Conference will be organized on 5^th-6^th January 2022.

Third Quarter 2021 Results by CRC – How was the quarter?

CRC announced third quarter 2021 results on 11^th November 2021. The company reported a net income of $103 million. Not only this, but the company generated $182 million in net cash from operations. In addition, CRC stated about $242 million in adjusted EBITDAX, and $131 million in free cash flow. The company has happily announced a Full-Scope Net-Zero Goal for 2045, which targets Scope 1, Scope 2, and Scope 3 emissions.

Moreover, they have also filed second permission to the EPA for the 26R reservoir, which, when coupled with our first permit for the A1/A2 reservoirs, forms Carbon TerraVault. Lastly, CRC is trying to maximize shareholder value while implementing the ESG approach through these activities. 

So what?

In terms of free cash flow generation, the third-quarter results managed to show solid operational performance and were the best of the year. As a consequence of these financial successes, CRC was able to implement a quarterly cash dividend to further strengthen the shareholder return plan. Furthermore, the company has raised full-year free cash flow projection from $460 to $510 million. Last but not least, CRC added a fourth rig in the Buena Vista Shale, due to the strength of the drilling plans for 2021.

Second Quarter 2021 Results – What’s new?

CRC reported second-quarter 2021 results on 5^th August 2021. The company reported a net loss of $111 million. Moreover, the company generated $127 million in net cash from operations. Not only this but the company has made progress on the ESG approach. CRC is excited to share that they have discovered nearly one billion metric tons of CO2 permanent storage potential, as well as up to 1,000 megawatts (MW) of front-of-the-meter solar options. Lastly, the team is also working with SunPower on a 12-megawatt (MW) behind-the-meter solar project, with the potential to grow to 45-megawatts.

How’s the CRC’s quarter?

The company’s second-quarter results were fueled by solid financial and operational performance. Not only this, but CRC raised its 2021 free cash flow projection to $400 to $500 million. Lastly, the company is raising the Share Repurchase Program from $150 million to $250 million too.

HOOKIPA Pharma Inc. (HOOK) experienced a decrease of  5.82% in the aftermarket. However, the last trading session closed at $2.92 with a decline of 7.01%.

JMP Securities Hematology and Oncology Summit

HOOK announced on 3^rd December 2021 that the company’s management team will take part to attend virtual investor meetings and speak at The JMP Securities Hematology and Oncology Summit on December 6-7, 2021.

 Third Quarter 2021 Results – What’s up?

HOOK reported third-quarter 2021 results on 10^th November 2021. The company had $82.7 million in cash and cash equivalents. Moreover, the revenue came out to be $3.9 million. Moreover, general, and administrative costs came out to be $4.3 million. The drop was mostly attributable to lower labor costs and lower professional and consulting fees.

The drop in personnel-related expenses was primarily due to lower stock compensation costs. They were somewhat offset by higher headcount and salaries in our general and administrative operations. Lastly, HOOK reported a net loss of $20.0 million, more than the net loss of $13.6 million for the same period in 2020. The rise was mostly due to increased research and development activity at HOOK.

HB-200 program – Newest Updates

On 9^th November 2021, HOOK announced that HB-201 has been advanced to Phase 2, where it will be tested in conjunction with pembrolizumab as a first- or second-line therapy for squamous cell head and neck malignancies. Moreover, the company reported that HOOK has begun a Phase 2 research to evaluate HB-201 in combination with pembrolizumab. In advanced head and neck cancer, interim Phase 1 HB-200 findings continue to indicate significant numbers of tumor-specific CD8+ T cells, promising early anti-tumor activity and a tolerable tolerability profile.

Furthermore, HOOK is developing an immuno-oncology pipeline for a variety of diseases, including HB-300 for prostate cancer and HB-700 for KRAS-mutated tumors. Last but not least, the company is investigating collaboration prospects for continuing development of HB-101 after interim Phase 2 findings reveal consistent immunogenicity, tolerance, and decrease in CMV viremia in kidney transplant patients.

About HOOK

HOOK is a clinical-stage biopharmaceutical company developing innovative immunotherapies that mobilize and enhance specific T cells and antibodies. This will help fight or prevent catastrophic illness. Moreover, HOOK is working on a number of possible first-in-class arenaviral immunotherapies for cancer and infectious illness. The company is developing arenaviral treatments that produce strong antigen-specific CD8+ T cells.

Vicarious Surgical Inc. (RBOT) saw a push of 14.14% in the aftermarket. However, the last trading session closed at $10.47 with a decline of 18.2%.

Third Quarter 2021 results by RBOT – What’s happening?

On 8^th November 2021, RBOT announced third quarter 2021 results. Operating costs for the third quarter of 2021 were $8.6 million, $3.3 million more than the same quarter the previous year. Moreover, R&D costs were $5.2 million in the third quarter of 2021, $2.5 million more than the third quarter of 2020. Not only this but the general and administrative costs came out to be $2.5 million. Lastly, the company reported cash and cash equivalents of $185 million.

How’s the quarter been?

This quarter commemorates the company’s initial public offering, and the company is extremely proud of the teams and workers for their contributions to the company’s success so far. RBOT is in a strong position to continue developing the next-generation robotics system. Not only this, but the team is delighted to report that they have just submitted a thorough regulatory strategy with the FDA in the form of a pre-submission.

Long-Term Lease – More About it

On 20^th October 2021, RBOT announced the signing of a long-term lease deal in Waltham, MA, for an additional 30,000 square feet. The new facility will boost production capabilities and incorporate four demonstration and testing operating rooms. The facility is situated adjacent to Vicarious Surgical’s offices, and it is the company’s second structure on its growing site.

What’s Next?

Vicarious Surgical will be able to double its capacity for research, testing, and production as a result of the expansion. Lastly, this facility is an important milestone in the journey to invent, market, and expand the company.

About RBOT

RBOT, founded in 2014, is a revolutionary robotics business working to improve surgical process efficiency. Furthermore, the company’s innovative surgical method combines patented human-like surgical robots with virtual reality to send surgeons inside the patient for minimally invasive surgery. The FDA has given the Vicarious System Breakthrough Device Distinction, making it the first surgical robot to acquire this designation.

Aeglea BioTherapeutics, Inc. (AGLE) experienced an incline of 8.33% in aftermarket. However, the last trading session concluded at $6 with a decrease of 2.76%.

AGLE to Report Phase 3 Topline Results of Pegzilarginase – When?

AGLE announced on 5^th December 2021 that the company will hold an investor conference call and webcast to present the topline results from the PEACE Phase 3 clinical study of pegzilarginase in individuals with Arginase 1 Deficiency. Moreover, the conference will take place on 6^th December 2021 at 8 a.m. ET.

New Appointment to Board of Directors – What’s the new update?

On 16^th November 2021, AGLE reported that Hunter C. Smith has been appointed to the Board of Directors. Mr. Smith will be responsible to handle certain duties such as senior leadership, corporate strategy, and financial management of commercial operations. Moreover, he has been the company’s chief financial officer since 2017 and served as temporary CEO from March to July 2020.

Prior to joining Rhythm, Mr. Smith served as vice president, finance, and chief financial officer of Celgene Corporation’s inflammation and immunology business segment. Last but not least, he graduated with honors from Northwestern University with a B.A. in history and an M.B.A. in finance from New York University’s Stern School of Business.

Now what?

Smith joins the board of directors and the AGLE family with great enthusiasm. He has extensive biotech leadership expertise, including corporate strategy, global market planning, and product innovations. Not only this, but his participation on the board will provide everyone with tremendous insight and expertise as the team will work to provide human enzyme therapy to those suffering from uncommon metabolic illnesses.

Third Quarter 2021 Results – Latest Updates

AGLE announced the third quarter 2021 results on 4^th November 2021. The company reported that it had cash and cash equivalents of $114.3 million. Moreover, AGLE reported development fee revenues of $1.4 million in the third quarter of 2021. The research and development costs for 2021 and 2020 totaled $14.9 million and $12.5 million, respectively. The increase was largely due to the completion of enrolment in our Phase 3 PEACE study of pegzilarginase for the treatment of persons with Arginase 1 Deficiency.

Furthermore, general, and administrative costs were $6.8 million, compared to $5.7 million in the third quarter of 2020. The company’s commercial capabilities and infrastructure were principally responsible for this rise. Lastly, the net loss was $20.3 million and $18.0 million, respectively.

How was AGLE’s quarter?

AGLE thinks that they have made considerable progress in all of the initiatives this year, and they are looking forward to the results of the Phase 3 clinical study of pegzilarginase in Arginase 1 Deficiency.

Histogen Inc. (HSTO) has seen an incline of 5.01% in the premarket. However, the last trading session closed at $0.4352 with a decline of 2.68%.

Third Quarter 2021 Business Updates – Latest news by HSTO

On 10^th November 2021, HSTO announced the third quarter of 2021 business updates. HSTO began a Phase 1/2 clinical research of HST 003 in June 2021 to assess the safety and effectiveness of the human extracellular matrix. Moreover, the company kept moving forward with the efforts to assess other pipeline options. In addition, preclinical proof-of-concept investigations are now underway, with preliminary results expected in the fourth quarter of 2021. The company also announced the start of a strategic partnership process with partner Amerimmune to further the development of emricasan in COVID-19 patients with mild to moderate symptoms.

CEO Transition by HSTO – All About it

HSTO reported on 8^th November 2021 that Steven J. Mento has been appointed as the Executive Chairman and Interim President and Chief Executive Officer of the company. Dr. Mento was a co-founder of Conatus and served as the company’s president and CEO from July 2005 until the merger. Moreover, he has worked in the biotechnology and pharmaceutical sectors for over 35 years in a variety of senior managerial and scientific roles.

Now what?

HSTO is sure that they have the cutting-edge technology, patented procedures, and the proper strategy to be a leader in restorative treatments. However, the company also intends to add value to the portfolio of caspases by continuing to develop it. They are confident that Steve’s previous leadership expertise and track record will ensure a smooth transfer at this time.

HSTO and Amerimmune to present data in COVID

On 2^nd November 2021, HSTO announced that Amerimmune will provide updated results from the emricasan Phase 1 research in mildly symptomatic COVID-19 patients. In a small group of COVID-19 patients who received orally-dosed emricasan, the Phase 1 study revealed outstanding safety in early-stage, moderately symptomatic patients.

When compared to the placebo group, Emricasan reduced clinical symptoms and accelerated recovery from COVID-19. Furthermore, Amerimmune’s first identification of disease-related indicators allowed HSTO to concentrate on learning how the virus impacts the immune system.

Chindata Group Holdings Limited (CD) experiences a decrease of 7.71% in the premarket. However, the last trading session concluded at $8.82 with a decrease of 1.78%.

Third Quarter 2021 results of CD – What’s up?

CD reported third-quarter 2021 results on 24^th November 2021. The total revenues climbed by RMB740.8 million i.e., US$115.0 million in the third quarter of 2021. Moreover, the total cost of revenue climbed to US$65.6 million in the third quarter of 2021. It is primarily due to increases in utility costs and depreciation and amortization charges. Lastly, selling and marketing expenditures fell 22.4 percent to US$4.2 million in the third quarter of 2021.

 Now what?

CD generated another quarter of strong financial results. As the company continued to help and accompany the clients in their quest for success, their business model remained efficient. Moreover, the growth momentum continued robust in the quarter.

Profitability was consistent, and it was among the industry’s best performers. The adjusted EBITDA margin was in the upper 40s, at 49.7%. The net income was positive for three quarters in a row, at a margin of 10.6%. Lastly, the CD will continue to guarantee that they have varied finance in place to support the development both in China and abroad in the future.

Zero-carbon solutions by CD – All about it

On 10^th November 2021, CD announced that it was asked to speak at the International Chamber of Commerce’s Make Climate Action Everyone’s Business Forum, which runs concurrently with the UN Climate Change Conference (COP26). In response to climate change, CD shared its zero-carbon digital infrastructure efforts with industry leaders, organizations, and NGOs in Asia-Pacific growing markets.

CD is delivering net-zero carbon emissions solutions for digital infrastructure in China, as China’s first technology business to present a precise carbon-neutral path. Furthermore, direct green power trading, unique regional green power consumption mechanisms, and the construction of renewable energy power plants.

Strategic dialogue with the Climate Group

On 29^th October 2021, it was reported that Alex Ju, the founder of CD, met with Helen Clarkson, the CEO of the Climate Group, for a strategic conversation. They discussed the necessity of digital infrastructure in enabling global growth and the role of internet technology businesses in decreasing carbon emissions. Moreover, Helen Clarkson thanked CD for joining the RE100 program and praised the company’s ongoing commitment to zero-carbon computing power.

FSD Pharma Inc. (HUGE) saw an increase of 2.36% in the premarket after the announcement of Positive Effects of Lucid-MS. However, the last trading session closed at $1.27 with an increase of 8.55%.

Positive Effects of Lucid-MS – New updates

On 2^nd December 2021, HUGE shared the preclinical data, accompanied by an explanation video, illustrating the potential disease-modifying benefits of Lucid-MS. It is the Company’s primary medication candidate for the treatment of multiple sclerosis. Lucid-MS is a patented neuroprotective novel chemical entity that alters protein citrullination and myelin structure. Furthermore, the Company has published a film outlining its pre-clinical achievements in addition to showing the Lucid-unique MS’s potential therapeutic usefulness.

New Appointment by HUGE – See who’s this?

On 16^th November 2021, HUGE reported that Eleanor N. Fish has been appointed to the research and clinical advisory board. Dr. Fish is an experienced immunologist and member of the Government of Canada’s Expert Scientific Panel to the Chief Scientific Advisor. Lastly, he brings his valuable experience to HUGE that will help the business focus on developing FSD-PEA, and Lucid-MS.

What’s next?

Firstly, the company welcomes Dr. Eleanor Fish to the team. One of Eleanor’s main goals is to learn more about the onset and management of autoimmune disorders like multiple sclerosis and rheumatoid arthritis. Secondly, her long experience in translational research will tremendously benefit FSD’s existing and future pipelines. Thirdly, her skills and insights will be highly important as the company continues to progress the FSD-PEA and Lucid-MS initiatives.

Agreement of HUGE and Covar Pharmaceuticals – More About it

On 19^th October 2021, HUGE stated that it has signed an agreement with Covar Pharmaceuticals Inc. This is a contract research and production services organization, to begin supplying research quantities of FSD’s therapeutic candidate. This agreement with Covar keeps us on track to finish extensive preclinical research and scale-up activities. Lastly, this might pave the way for the company to move Lucid-PSYCH from the bench to the clinic.

About HUGE

HUGE is a life sciences company with two fully-owned subsidiaries focused on developing a portfolio of varied therapeutic assets as well as new healthcare and biotech services. Moreover, it is a specialized biotech pharmaceutical R&D firm focusing on discovering uses for ultra micronized PEA, the company’s flagship ingredient, by down-regulating cytokines to induce an anti-inflammatory effect.

Tilly’s, Inc. (TLYS) experienced an incline of 6.38% in the pre-market following the announcement of third-quarter results. However, the last trading session concluded at $14.43 with an increase of 1.33%.

Third Quarter Results in 2021 by TLYS – Latest Updates

TLYS reported third-quarter results in 2021 on 2^nd December 2021. The report says that total net sales were $206.1 million. Physical store net sales increased by $60.7 million owing to a much more routine back-to-school season this year, which was devoid of pandemic-related closures. Not only this, but the company has 243 total stores at the end of the third quarter this year, compared to 238 at the same time the previous year.

When compared to last year’s $35.7 million, e-commerce net sales increased by $5.1 million, or 14.3 percent. Gross profit was $76.7 million, $40.7 million more than that of the previous year. In addition, the SG&A expenditures were $47.7 million compared to $37.1 million the previous year. Last but not least, the large rise in net sales caused the operating income to increase to $29.0 million as compared to $3.5 million.

What’s Next?

So far, fiscal 2021 has been a record-breaking year for TLYS, which attributes to the great product selection, an improved consumer purchasing climate, and the whole team’s hard work and devotion.

Moreover, net sales and profits per share have both set new highs in each of the first three quarters. The fourth quarter is off to a solid start, and despite the perceived obstacles, the company is confident about the investment opportunities for the rest of fiscal 2021 and into fiscal 2022.

New Appointments by TLYS – What’s going on?

On 20^th October 2021, TLYS announced the appointment of Teresa L. Aragones and Erin M. Chin to the company. Ms. Aragones has a combined 25 years of expertise in digital and brand marketing. She is the Chief Marketing Officer for Discord, a popular online chat service for teenagers. Prior to joining Discord, she worked as the Chief Marketing Officer at Visual Supply Company, a mobile picture software company. She formerly worked at Nike and Volkswagen as a Director of Marketing.

Ms. Chin also has a lot of expertise in building and managing lifestyle brands. She presently works at Logitech as the Chief Marketing Officer for the Streamers & Creators division. She formerly worked as the Senior Brand Marketing Director for PepsiCo’s Mountain Dew brand. Furthermore, Ms. Chin started her career at Goldman Sachs as an investment banker in the information and communication sector.

Domo, Inc. (DOMO) experienced a decline of 10.97% in the aftermarket following the announcement of third-quarter 2021 results. However, the last trading session concluded at $65.15 with an incline of 1.43%.

Third Quarter 2021 Results by DOMO – What’s going on?

DOMO announced third quarter 2021 results on 2^nd December 2021. Total sales were $65.1 million, 21% more than the previous year. Moreover, subscription income increased by 21% year over year to $56.6 million. Not only this, but the income from subscriptions accounted for 87 percent of overall revenue.

Billings also increased by 26% year over year to $70.2 million. Furthermore, the remaining performance obligations (RPO) were $296.9 million, 19% more than the previous year. The operating operations also generated $0.03 million in net cash. The GAAP subscription gross margin was 81 percent and the non-GAAP subscription gross margin was 83 percent.

So what?

DOMO had a good quarter, fueled by increased demand for data-enabled apps to assist the clients to operate their companies on the Domo platform, as well as ongoing market demand for the core contemporary BI product.

DOMO being the leader – What’s up?

On 22^nd November 2021, DOMO stated that it was ranked first in Nucleus Research’s Embedded Analytics Technology Value Matrix for 2021. Everyone honors DOMO because of its widespread corporate acceptance, simplicity of integrating sophisticated features, and the platform’s complete, end-to-end nature, which spans the whole data pipeline. Domo’s investments in new and expanded capabilities, which increased the platform’s value, also helped the firm earn a solid lead on the 2021 Value Matrix.

What’s next?

The desire to use data to build and create new value is rising among both consumers and businesses. However, Domo’s embedded analytics solution is part of a larger push to make data more convenient for everyone and to change the way businesses are managed.

New addition to Board of Directors

On 4^th November 2021, DOMO reported that Jay Brown has been added to the Board of Directors. Mr. Brown is a creative businessman and business executive who co-founded Roc Nation, a full-service entertainment company, in 2008. He currently serves as vice-chairman, overseeing the company’s growth. Jay has been responsible for the creation of multibillion-dollar brands for more than 25 years and will continue to do so. He is on the boards of many organizations, including the Hammer Museum, Global Citizen, and CLF. Lastly, Mr. Brown succeeds Mark Gorenberg, who has been a member of Domo’s board of directors for the previous decade.

Is it worth it?

The company thinks that Jay’s contacts, brand knowledge, and direction will be invaluable in helping the business as it strives to develop the business and continue to harness the equity DOMO has built in the consumer experience.